Icahn's $5.4 Bil. Bid For Mylan Leaves Door Open To A "White Knight" Suitor
This article was originally published in The Pink Sheet Daily
Executive Summary
Investor offers $20 per share, a 17% premium over Mylan's closing price a day earlier. Icahn suggests other pharma companies are potentially interested in buying the generic drug maker and is proposing an acquisition contract with no break-up fee so that Mylan could pursue other offers.
You may also be interested in...
Mylan Will Remain Independent, Board Says In Rejecting Icahn Buy-Out
A response to Icahn's proposed $5.4 bil. bid appears to shut the door to potential "white knight" pharma company suitors that were invited through Icahn's offer. Mylan does not consider Icahn's bid "serious"; in response, High River says it would put $1.5 bil. in equity into the deal.
Mylan Will Remain Independent, Board Says In Rejecting Icahn Buy-Out
A response to Icahn's proposed $5.4 bil. bid appears to shut the door to potential "white knight" pharma company suitors that were invited through Icahn's offer. Mylan does not consider Icahn's bid "serious"; in response, High River says it would put $1.5 bil. in equity into the deal.
King's Review Of Product Returns Could Scuttle Mylan Merger
Both companies say the issues stem from historical practices and will not affect King's business going forward. Mylan says it remains committed to acquiring King but seeks further quantification of any financial restatement relating to King's recognition of product returns.